



THE EMERGENCE OF TIME PROGRAMMED DRUG DELIVERY SYSTEM: CHRONOTHERAPY OF 
CARDIO VASCULAR DISEASES 
Review Article 
 
VITASTA SINGH1, ASHWINI DESHPANDE
*School of Pharmacy & Technology Management, SVKM’s NMIMS, Shirpur Campus Babulde, bank of Tapiriver, Shirpur 425405, Dist. 
Dhule, Maharashtra, India. 
Email: ashwinideshpande4@gmail.com 
*  
Received: 08 Aug 2014 Revised and Accepted: 10 Sep 2014 
ABSTRACT 
Time programmed drug delivery system is a system that promises to deliver a drug at a point of time when it is most required, as it is programmed 
beforehand. Though the delivery system is a boon to the pharmaceutical research due to its desired release profile feature and application to 
numerous disease areas like hypercholesterolemia, asthma, cardiovascular disease, peptic and duodenal ulcers and cancers of various categories, its 
special significance is due to its potential applications in chronotherapeutic drug delivery, where the pinnacle aim of devising this drug delivery 
system is to obtain a programmed release at desired time points, with a lag time where no drug is released. Lot of work is being carried out lately, to 
understand the relationship between the rhythmicity in disease symptoms and the biological clock, but a special mention is required in case of 
diseases associated with cardiovascular functions. Cardiovascular system works on a frequency cycle and it resonates hour to hour with the 
biological clock except in cases of disturbances from any external stimuli, which leads to CVS disorders. Correcting the rhythmicity of the frequency 
cycles of heart, which are apparently in sync with the master clock, can be done or achieved by delivering the drug exactly at the point of time when 
it is needed the most. This will minimize the side effects and maximize the benefits of the administered dose. This review focuses on the importance 
of circadian rhythm and chronotherapy in the management of CVS and overall physiology, scientific evidences of their relationship, role and 
importance of PDDS in formulation management and finally the work done in this direction and the marketed chronotheraptics delivery systems 
available for CVS disorders. 
Keywords: Pulsatile drug delivery system, Chronotherapy, Cardiovascular diseases, Pulsatile technology. 
 
INTRODUCTION 
Industrial pharmacy came into the picture when researchers realised 
that the “eureka” moment of discovering a drug molecule is insufficient 
to convert a drug into a delivery system. That simply lipophilicity and 
hydrophobicity can not decide the fate of a molecule, through its journey 
of getting transformed into a successful dosage form. Also, various health 
conditions, disorders and diseases don’t basically respond to a drug but 
to a delivery system and the failure of delivery system becomes the 
failure of the drug. Though still maximum drugs were doing well with 
their immediate release profiles, conditions like cancer and AIDS were 
continuously challenging the researchers to make the specific delivery of 
such drugs more efficient. So controlling the release of the drug through 
the delivery system came into picture in 1960s via mucosal inserts, 
implants (e. g., subcutaneous or intramuscular), oral capsules (release in 
the GI tract), topical patches (applicable on skin), and they were getting 
approved for clinical use[1]. The time period between 1980s and 90s 
became the era of controlled release delivery and selective drug 
targeting. The huge popularity of controlled release delivery systems and 
drug targeting at that time, also brought Ehrlich's imagined concept of 
the "Magic Bullet" to certainty [1]. After the increasing success of 
controlled delivery systems, Time controlled drug delivery came as a 
bifurcation and modification of the same, as it was realised that 
ordered/structured release may not always be the requirement of the 
disease condition, but tailor made burst release may be required, by 
some diseases, as per the disease pathophysiology and on-set patterns. 
This gave rise to time sensitive drug delivery systems which promised to 
deliver the drug at a particular time of the day, as per the need of the 
regimen. The situation demanded release of drug as a "pulse", after a 
time lag, such that the design gives complete and rapid drug release 
followed by the intentional lag time. Such systems came to be known as 
pulsatile drug delivery systems (PDDS), time-controlled systems, or 
sigmoidal release systems. Time controlled systems have been 
developed in close association with emerging chrono therapeutic 
delivery ideas, after it was confirmed by many clinical studies that the 
symptoms of several pathophysiological conditions, as well as the 
pharmacokinetic and pharmacodynamic profiles of most drugs, are 
subject to rhythmic or circadian variation patterns. 
Section 1: Chronopharmacology: Basis of Chronotherapeutics 
and time programmed drug delivery 
Biological processes and functions are anatomically and physically 
present into three dimensional spaces and the biological time 
structure is synchronised with spatial time[2]. This biological time 
structure is described as the biological rhythm and is characterized 
by short, intermediate, and long period oscillations [2]. The 
biological rhythms occur endogenously and are self sustainable in 
nature and are predominantly characterised by period, level, 
amplitude, and phase. ultradian (20 hr), circadian (24 hr), and 
infradian (28 hr) rhythms define the periodicity of the biological 
rhythms[2]. Among these periodic rhythms, the 24 hr cycle i. e the 
circadian pattern is most important for the practice of medicinal 
pharmacotherapy of patients owing to its parallel nature with the 
clock time cycle. Numerous biological rhythm studies have helped 
delineate the temporal organization of humans and human circadian 
time structure can be best portrayed by synchronising it with 24-hr 
rhythms on a time line as shown in figure 1[2]. 
 
Fig. 1: Human circadian time structure showing the evidence of 
synchronization between certain selected biological variables 
with the 24 hour clock. 
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Clinical evidence supports the fact that Circadian rhythms influence 
mammalian physiology. The prime function of the circadian rhythm 
is to optimize cellular processes along with optimization and 
coordination of various metabolic processes and human behaviour 
regarding its sleep wake cycle. The Circadian Time System is 
hierarchically structured along the master pacemaker located in the 
superchiasmatic nucleus of the hypothalamus[3,4]. This master 
pacemaker located in hypothalamus controls and coordinate with 
the others peripheral clocks located in different tissues and cells[3]. 
Playing a key role in normal physiology and behaviour is not the 
only function of the circadian clock, but according to many reported 
clinical studies, it has been found that abnormalities in the circadian 
rhythm are associated with the pathophysiology of various diseases 
including asthma, cardiovascular diseases, diabetes, cancer, 
autoimmune disorders and various psychological conditions[5]. 
Many molecular targets and biochemical signals inside the cells are 
expressed in sync with the circadian rhythm which can affect the 
bioavailability, potency and efficacy of many drugs[6]. A 
considerable number of genes, drug receptors and metabolizing 
enzymes are expressed in circadian manner, leading to a significant 
lag in their efficacy related to the time of the day at which they are 
administered, which gives sufficient evidence of circadian rhythm 
playing an important role in the biochemical action of the drug. 
Chronotherapeutics is the purposeful delivery of medications in 
unequal amounts over time[2]. Chronotherapeutics takes into 
account rhythm determinants in (i) disease pathophysiology 
(chrono pathology), (ii)chronopharmacology (chronokinetics, 
chronodynamics, chronesthesy, and chronotoxicology) of 
medications, and (iii)attributes (period, phase, amplitude, and level) 
of the human circadian time structure to determine the drug-
delivery pattern,dose, and administration time to optimize desired 
and/orminimize adverse effects[1]. Figure 2[3] signifies the relative 
function of chrono reception center in the human brain to the 
activities that it coordinates. 
 
 
Fig. 2: Chronobiology of Super Chiasmatic Nuclei (SCN), the 
centre for chrono reception 
 
Chronotherapeutics is a treatment process in which bioavailability 
of the drug administered, will depend upon the time at which it is 
administered, with regards to the rhythmic activity of the symptoms 
of the disease condition for which the drug is administered, in order 
to maximize its health benefits and minimize the side effects. 
Whether a disease, symptom or condition can be treated with 
Chronotherapy, will depend upon the fact that whether there is any 
co- dependence between the peak-to-trough rhythmic activity in 
disease symptoms and associated risk factors, and pharmacokinetics 
of the drug[5]. 
The potential benefits of chronotherapeutics till now has been 
reported in the management of a number of diseases like cancer, 
cardiovascular diseases, allergic rhinitis, rheumatoid, asthma, cancer 
and peptic ulcer[9]. Among them the most noticeable is the 
chronotherapeutics of cardiovascular system owing to their visible 
rhythmicity(blood pressure, heart rate, pulse) with time and 
space[2,5]. 
As more about the subject of chronobiology and 
chronotherapy is being understood, the fashion in which a dosage 
regimen is designed and the time prescribed at which the Patient 
shall take the medication, is a matter of concern today more than 
what it was in the past[5,7]. The custom of prescribing medication 
several times a day in order to maintain its even concentration in 
blood, seems to be changing now as researchers are coming in 
agreement with the fact that certain medications can work better if 
taken in synchrony with the coordinated day night cycle and 
respective biological rhythms[8]. 
This review will cover the potential, scope and emergence of 
chronotherapeutic drug delivery in cardiovascular diseases and the 
candidate drug delivery systems suitable to realise the required 
interventions. 
Cardiovascular system and Chronotherapy: The association 
The cardiovascular system is highly organised in time; blood 
pressure (BP), heart rate (HR), peripheral resistance, or activities of 
vasodilating hormones, all display pronounced circadian 
variations[8]. Pathophysiological events like sudden cardiac death, 
stroke, ventricular arrhythmias, arterial embolism, and symptoms of 
coronary heart disease such as myocardial infarction and ischemia, 
angina attacks in case of stable angina or variant angina or even in 
silent ischemia, do not occur arbitrarily, instead they have been 
found to show circadian phase dependency at the time of dose 
administration[9]. Beta-blockers, calcium channel blockers, oral 
nitrates and ACE inhibitors, all show a time dependent efficacy 
patterns[9]. In a clinical study by lemmar et al, it was shown that 
beta adrenoreceptor blockers, oral nitrates and calcium channel 
blockers display action depending upon the time of the day at which 
they were administered[5]. In the case of hypertension, the 
pharmacology behind that could be the increased levels of nor 
epinephrine at night which leads to the morning rise in BP as the 
concerned receptors of norepinephrine are expressed in a high 
concentration at that time of the day. This rise in epinephrine at 
night is a case of disturbed circadian rhythm[10]. 
Rhythms of the cardiovascular system: foundation of 
chronotherapy 
Heart rate was among the first physiological function which was 
reported to have irregularity in pattern through the sleep wake 
cycle[8,9]. Variation in pulse rate and its hasty increase in early 
mornings, also called as the morning surge, were reported as earlyas 
in the starting of the 17th
A clinical survey of 7731 patients, who were initially being treated 
for Thrombolysis in Myocardial Ischemia, also produced the 
evidence for a circadian variation in the onset of pain with a 
maximum between 6:00 hr and 12:00 hr and it was observed both in 
patients with unstable angina and patients with evolving non-Q-
wave acute MI[2]. 
 century[9,10]. In the 18th and 19th 
centuries general observations as well as detailed data on daily 
variations in pulse rate and pulse quality were reported[9,10]. 
Though the Rhythms of HR and BP are the most studied periodic 
functions in the cardiovascular system, there are other cardiac 
measurements that have been shown to exhibit circadian variations 
as well, for example, peripheral resistance, stroke volume, cardiac 
output, blood flow, ECG demonstrations in the plasma 
concentrations of pressor hormones such as norepinephrine, 
angiotensin, rennin, aldosterone, plasma cAMP concentration in 
blood viscosity and aggregability, and atrial natriuretic hormone[9].  
Section 2: Candidate drug delivery systems suitable for the 
realization of chronotherapeutic goals 
If time programming is concerned then the paramount available 
delivery system would be pulsatile. PDDS are being better 
recognized in pharmaceutical technology as they deliver the right 
dose at the desired time at a desired site[11-13]. The disease 
conditions for which PDDS is proving to be promising are duodenal 
ulcer, cardiovascular diseases, arthritis, asthma, diabetes, 
neurological disorder, cancer, hypertension and 
hypercholesterolemia[11,14,15]. The classification of PDDS includes, 
time controlled systems where the release is solely controlled by the 
delivery system, stimuli induced systems, in which the release is 
controlled by the internal or external stimuli, like PH induced or 
inflammation induced or enzyme induced[11,14,16]. In case of 
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chemically induced systems, stimuli can be electrochemical signals, 
magnetic impulse, ultrasound or irradiation[11,15]. 
Time controlled pulsatile release system  
These time-controlled systems can be classified as singular (tablet or 
capsule)systems or multiple systems.  
Singular systems  
Pulse-in-cap system [11, 17] 
Different PDDS single-unit systems have been developed so far. The 
design of this kind of system includes an insoluble capsule body 
containing a drug and a plug[11,17]. The role of the plug is to create 
a lag time, which is pre-programmed, and remove itself later either 
by dissolution, swelling or erosion[11,17]. Illustration of single unit 
system is The Pulsincap® system, in which the capsule body is 
water insoluble due to formaldehyde induced cross linking, and is 
filled with drug formulation[11,16]. Capsule body in these systems 
stay sealed where the plug opens. As the capsule body comes in 
contact with dissolution medium or gastro-intestinal fluids, the plug 
starts swelling which creates pressure on the capsule shell, and it 
bursts after the predetermined lag time, releasing the drug in the 
gastric or intestinal medium[11,14]. The time lag in these systems is 
controllable. By changing the size and position of the plug, the lag 
time can be modified[11,14]. Nagaraja G et al in 2013 have worked 
on the preparation of pulse in cap formulation of Losartan 
Potassium which is a first line antihypertensive drug, for the 
preparation of its chronotherapeutic drug delivery system[18]. 
Porous port systems  
The port system is called so because it creates porous opening for the 
entry of extracellular fluid or water. It contains an osmotically active 
agent in a gelatine shell capsule, which is coated with a semi 
permeable membrane and also contains an insoluble plug along with 
the drug formulation[11,16]. As water diffuses across the semi 
permeable membrane or as the capsule comes in contact with the 
aqueous medium, the osmotically active agent prevents the exit of 
water from the capsule shell[11]. This creates an internal pressure 
inside the capsule that eventually ejects the plug, after a 
predetermined lag time. As a general rule, more will be the thickness 
of semi permeable membrane, more will the time lag. The advantage of 
this system is its high degree of correlation with the in vivo 
experiments[11]. 
Modified solubility systems 
These systems contain a solubility modulator which is responsible 
for the pulse in the delivery system. The solubility modulator 
prevents the solubility at a particular pH or any other kind of 
stimulus induced solubility[11,14]. The system consists of a drug 
along with a modulating agent and also sodium chloride which acts 
as an Osmogen. The quantity of NaCl in the system is adjusted in 
such a way that saturation of the delivery system does not take place 
as it contacts the aqueous medium[11,14]. The solubility of the drug 
will depend upon the amount of solubility modulator added in the 
system, which in turn is responsible for the pulse in the delivery 
system[11]. The advantage of the system is that it is not restricted to 
a certain class of drug but in fact can be used for a large number of 
drugs. 
Reservoir delivery systems 
Mostly pulsatile drug delivery systems are reservoir systems. A 
certain coating of polymer is done to prevent the drug from bursting 
before time and this coating layer can be called as a plug layer. This 
plug tends to dissolve or wear out after a certain programmed lag 
time which leads to rapid drug release. The lag time is proportional 
to the thickness of the plug layer. 
The Time Clock® system[11]which is a reservoir system comprises 
of a solid drug on which there is a lipid coat of carnauba wax, bees 
wax and surfactants[11]. The lipid layer prevents the release of drug 
in a hydrophobic environment and the surfactant used, such as 
polyoxyethylene sorbitanmonooleate will help the rapid release of 
the drug in the desired environment [11]. The emulsification of the 
coat takes place in the aqueous environment. This will lead to the 
dispersion of the core in the aqueous environment. Time taken for 
the coat layer to dissolve in the aqueous environment will depend 
upon the thickness of the film. Easy manufacturing without the use 
of any sophisticated instrumentation is an advantage of this type of 
delivery system. 
Another classic example of reservoir delivery system is The 
Chronotropic® system[11] which consists of a drug trapped in a core 
which is further coated with a release retardant and swellable 
polymer such as hydroxypropylmethyl cellulose (HPMC), which 
retards the onset of drug release by offering a desired lag 
time[11,14]. Lag time offered by the delivery system will depends 
upon the thickness and the viscosity grade of HPMC used[11]. 
Formulation of all types of solid dosage forms can be achieved by 
this system. 
Multiple systems  
Multiple drug delivery systems mainly consist of small discrete units 
in which the drug is trapped. The small discrete units are 
independent in nature and more than a single active ingredient can 
be incorporated in them. They are useful for the combination drugs 
which are incompatible with each other. The advantages of multiple 
systems include multiple drug administration, small size, reduction 
in dose, and accuracy in transit time in different subjects, better 
stability and finally reduced side effects due to minimum drug 
interaction used together in formulation. The loopholes in the 
system include non reproducible results in manufacturing capacity, 
several formulation steps, use of specialised instruments and high 
cost of production. 
Pulsatile delivery by change in membrane permeability  
Membrane permeability is a common method to modify release in 
many delivery systems. In case of polymers containing quaternary 
ammonium compounds, membrane permeability can be brought 
about by addition of counter ions in the polymer[11,14]. 
hydrochloride counter-ions are coupled with polymers containing 
quaternary ammonium compounds to manipulate their membrane 
[11,14]. The ammonium group in the acrylic polymer is hydrophilic 
in nature so it assists the polymer to interact with water and change 
its permeability so that it permeates the underlying core[11,14]. 
Example of acrylic polymer containing quaternary side chain is 
Eudragit 30D and is reportedly the most widely used polymer to 
construct this delivery system. 
Sigmoidal release system [13] 
Sigmoidal release systems have been developed to achieve time 
controlled drug delivery in the intestine. It utilises pellets of succinic 
acid coated with ammonio-methacrylate copolymer which when 
released in intestine gives a typical sigmoidal release curve[11]. The 
velocity at which water enters the delivery system controls the lag 
time to be achieved by the system. Water dissolves the acid and the 
drug inside the delivery system and thus this solution formed 
increases the permeability of the polymeric coating[11]. The 
different types of acids that can be used in the formulation of 
sigmoidal release system are succinic acid, glutaric acid, acetic acid, 
citric acid, tartaric acid and malic acid[11,14]. 
Burst coat pulsatile delivery system 
Non-pareil sugar seeds are coated with an erodible and swellable 
polymer followed by a coat of insoluble polymer[11]. The swelling 
agents used aresodium starch glycollate, sodium carboxymethyl 
cellulose, L-hydroxypropyl cellulose, etc[11]. As water enters, the 
swellable layer starts expanding, which result in the burst of the film 
followed by rapid drug release, which is independent of medium pH 
and drug solubility. 
Time controlled expulsion system [11] 
The formulation contains the drug, a low bulk density diluent, 
mineral oil and disintegrant, and is further coated by an enteric 
polymer for example cellulose acetate[11,14]. As the dosage form is 
immersed in an aqueous medium, water starts penetrating the core 
and displacing the lipid material. As the lipid material gets 
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completely out of the delivery system, internal pressure in the 
dosage form raises enough to generate stress, resulting in the 
breakage of the coating material and release of drug from the 
system[11,14,16]. 
Apart from time controlled pulsatile delivery systems, there are 
many other variations to pulsatile delivery system which are 
advantageous in making modified release dosage forms. These 
include the following. 
Stimuli induced pulsatile release system  
During environmental changes like change in solvent composition, 
temperature, ionic strength and electric fields, some of the polymers 
undergo phase transition and display swelling de-swelling effects. 
Such environmental changes act as internal stimulus for the release 
of the dosage form. In case of gels, these stimuli, that is, the 
environmental changes, bring drug release as a response which may 
swell-deswell or rupture as a response to the stimuli. As the fluid 
phase gets saturated inside the gel, it forces the drug out of it and 
this is a possible mechanism of action of drug release from this 
delivery system[11]. 
Chemical stimuli induced pulsatile systems  
Hydrogels[11,14,2] 
There are many bioactive compounds within the body. Certain Novel 
gels have been introduced whichact in proportion to the 
concentration of the bioactive compounds in the body to modify 
their swelling and de swelling behaviour[11,14]. Gels forming cross 
linkage units by antigen anti body complexation should be given 
special mention in the category of novel gels since this type of cross 
linking is very specific in nature. Both polymerized antibodies and 
naturally derived antibodies have affinity towards specific antigens 
in the body, but the specific swelling and de swelling behaviour is 
attributable to the difference in their association constant [11,14].  
PH sensitive drug delivery system [11,14,16] 
This PDDS acts at a specific site which has an accepted pH range, and 
has two components merged in a single system. The first part 
consists of an immediate release section and the other contains a 
pulsed release section[11]. The pulsed release section releases the 
drug in response to change in pH as it’s a pH sensitive delivery 
system. pH dependency can be minimized by manipulating the 
system by coating with resistance polymers which resist release at a 
specific pH range[11,14]. Use of pH dependent polymers will ease 
the formulation of this type of delivery system. 
Specialized technology in pulsatile drug delivery system 
Chronotherapeutic Oral Drug Absorption System (CODAS) 
[8,10,11] 
Release its drug component after a prolonged period of time, after 
administration, is the primary aim of this technology. Verelan® 
which is a chrono therapeutic anti-hypertensive Virapamil 
formulation is an example of CODAS 8,
Spheroidal Oral Drug Absorption System (SODAS)[11,16] 
[10,11]. The drug release is 
approximately four to five hours after ingestion. The system consists 
of drug loaded beads which are coated with release controlling 
polymers. The amount of release-controlling polymer determines 
the total lag time. The polymer used in CODAS for controlling the 
release consist of two components, viz water soluble component and 
water insoluble component. As the fluid from the gastrointestinal 
tract comes in contact with the polymer coated beads, the water-
soluble polymer starts dissolving slowly as the system encounters 
the fluids in gastro intestinal tract, to let the drug diffuse, while the 
water insoluble polymer poses as a barrier layer to control the 
release and prevent burst effects. This controlled onset extended 
release delivery system provides peak plasma concentration in the 
morning hours, after a bed time administration, minimizing the 
morning surge in BP. 
This technology is based on the production of controlled release 
beads which are inherently flexible to accommodate different drugs 
due to its inherent flexibility, for the production of customized 
dosage forms[11,16]. This gives SODAS an edge to provide a number 
of tailored drug release profiles, including immediate release, 
extended release, sustained release and controlled release. The 
reverse can also be achieved by this technology i. e. the release can 
be delayed for a long number of hours which gives it a good scope 
for chronotherapy. 
The Intestinal Protective Drug Absorption System (IPDAS) 
[11,16,18] 
Masking of gastrointestinal irritant compounds is the primary aim of 
this high density multiparticulate tablet technology. High density 
controlled release beads compressed into a tablet form constitutes 
the basic structure of this delivery system. The tablet made with 
IPDAS® technology rapidly disintegrates and disperses its beads in 
the stomach. These beads pass gradually, in a controlled manner in 
the duodenum and the intestinal tract. The passage of beads from 
the stomach is independent of the feeding state. 
EURAND’s pulsatile and chrono release System [19,11,16] 
This system can be used where ever more than one pulse at 
predetermined lag time is required, as per the disease condition. 
This effect of the EURAND system can improve efficacy and 
minimize side-effects of a drug substance. The example of successful 
use of this technology, is in the formulation of circadian rhythm 
controlled release dosage form of propanalol hydrochloride, having 
a four-hour lag time before release after oral administration[19,11]. 
After bedtime administration, it shows a zero release phase of 
several hour sand is released in the early morning hours after initial 
delay in release, to achieve peak plasma concentration. 
Section 3: Challenges in formulation of cardiovascular 
chrotherapeutic dosage form 
The delivery system 
Cardiovascular diseases running in sync with the circadian rhythm 
often show an increase in symptoms in the early morning hours. 
This requires the formulation of a dosage form that can provide 
sufficient lag time after bedtime administration. Formulation of a 
dosage form that can successfully provide the long lag time without 
sinking or passing through gastric cavity before time, into the 
intestinal tract will give the desired effects expected out of the 
delivery system. This calls for the delivery system to float in the 
gastric media, which is quite a challenging task[20]. Moreover it 
requires specialized technology to achieve the desired effects in the 
dosage form. This may take an initial investment of capital in order 
to fulfil the goals of chrono therapeutic delivery dosage form. 
The active pharmaceutical ingredient 
Modification in the API is also an option to manipulate the time at 
which peak plasma concentration takes place. Classic example of the 
use of this approach can be of statins (HMG-CoA reductase 
inhibitors), which are anti hyper lipidimics[16]. Modification of the 
chemical structure of lovastatin by adding a methyl group makes 
simvastatin, which has a higher solubility than lovastatin[16]. 
Physiochemical modification of these compounds affects the time to 
reach the peak plasma concentration which is an indicator of the 
onset of action of the drug and its bioavailability. Other drugs used 
in cardiovascular diseases can be modified to deliver a time lag in 
their effect which is another method of formulating chrono 
therapeutic dosage forms but the task stays challenging. 
Section 4: Present chronomedication for cardiovasular diseases 
Chronotherapy of ischemic heart disease [21] 
Controlled-Onset, Extended-Release (COER)-Verapamil (USA: 
Covera HS™; other markets: Chronovera™)[21] is the first 
significant drug-delivery tablet for ischemic heart disease and 
hypertension chronotherapy. It got the approval from the United 
States Food and Drug Administration (FDA) in 1999 for 
marketing by the Searle Pharmaceutical Company. The 
technology used in this delivery system, delays the release of 
verapamil for approximately 4–5 h following the recommended 
bedtime ingestion[21,2]. Medication is released after this lag 
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time so that the highest blood concentration is achieved in the 
morning between 6 and 10 a. m., followed by an elevated drug 
level maintained throughout diurnal activity. The half-life of 
Verapamil governed by its active metabolite leads to a 
progressive decline of drug level in the evening and nocturnal 
phase, minimizing the concentration during the first half of 
nighttime sleep, when the risk of myocardial ischemia is low. 
Graded-Release Long-Acting Diltiazem[21,22] 
(Cardizem LA, Biovail Pharmaceuticals): This dosage form was 
approved by the United States FDA in 2003 for once-daily dosing 
at either time of the day. Multiple-dose studies of diltiazem has 
shown that the ingestion of the 360 mg dose of Cardizem LA at 
around 10 p. m during bedtime, results in a kinetic profile which is 
suitable for the chronotherapy of hypertension and IHD. The blood 
concentration level stays depressed during middle of the night, 
and then rises to achieve a maximum in the morning. An elevated 
drug level is maintained during the afternoon and early evening. 
multi-centre trial on Cardizem LA reported that bedtime 
administration of up to 540 mg/day is significantly more effective 
in controlling morning BP and HR than the ACE inhibitor ramipril 
taken at bedtime in doses of up to 20 mg/day. Cardizem LA has 
been found to have a good safety profile, and the occurrence of 
adverse events was in a dose-independent manner and 
comparable to the placebo treated group. The most common side 
effects were headache in around 11.7% subjects which was 
reportedly independent of dose followed by upper-respiratory 
infection in 5.6%, and lower-limb edema[4]. 
Chronotherapy of hypertension and arrhthymia 
The β-antagonist propranolol chronotherapy (Innopran XL™, 
Reliant Pharmaceuticals) [22,19] was approved by the united 
states FDA in the year 2003. This capsular dosage form results in 
trough drug blood concentration toward the midnight hours of 
night time sleep around 4.00 am and elevated plateau of drug 
concentration in the afternoon and early evening as reported by a 
multiple dose study[22,19]. Recent findings from 24-hour trials 
have documented potent chronotherapeutic systolic and diastolic 
BP reduction ability of this β-antagonist in the morning, with 
persistent BP-lowering activity throughout the entire 24-hour 
dosing interval. 
CONCLUSION 
Ace inhibitors, calcium channel blockers oral nitrates and beta 
adereno receptor blockers remain the key treatment options for 
the therapy of cardio vascular disorders. Multi centre clinical trials 
had revealed that COER Virapamil is therapeutic in both dipper 
and non dipper hypertension in a dose dependent manner and has 
a more desirable and efficacious release profile then the 
conventional Virapamil formulations[3]. Same goes for other 
marketed chronotherapeutic formulations of cardiovascular 
disorders. Though there are evidences for certain drugs in each of 
the above mentioned category to show no response in morning 
and evening dosing that can supposedly be seen as a negative 
response towards chrono therapeutic drug delivery, still first line 
treatment drugs (ACE inhibitors and ARBs) of major 
cardiovascular disorders like hypertension and myocardial 
infarction had shown tremendous response to the chrono 
therapeutic drug delivery. This calls for the need to improve the 
delivery systems for the existent drugs into modified chrono 
therapeutic delivery systems, in order to improve the overall 
treatment regimen of CVS disorders. Oral drug delivery remains the 
most popular and convenient mode of drug delivery. Treatment with 
modified chronotherapetic delivery system is equivalent in cost to 
the conventional once but has improved patient compliance due to 
decreased dosing intervals. PDDS offers a number of technologies to 
convert conventional DDS into chronotherapeutic systems. They 
should be utilized effectively in order to provide maximum benefit to 
the end consumer weather for cardio vascular diseases or any other 
diseases which can be treated chrono therapeutically for that matter. 
Abbreviations 
GI-gastro-intestinal, hr- hour, SCN- super chiasmatic nuclei, IHD- 
ischemic heart disease, ACE- angiotensin converting enzyme, ARB- 
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